{
    "clinical_study": {
        "@rank": "102676", 
        "arm_group": {
            "arm_group_label": "CLS003", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to\n      assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of\n      topically applied CLS003 in healthy subjects with cutaneous warts."
        }, 
        "brief_title": "First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts", 
        "condition": "Cutaneous Warts", 
        "condition_browse": {
            "mesh_term": "Warts"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects (male, non-pregnant female), 18 to 65 years of age, inclusive.\n\n          -  Body mass index (BMI) between 18 and 30kg/m2, inclusive\n\n          -  Fitzpatrick skin type I-II-III-IV\n\n          -  At least 4 cutaneous warts on the hands, separated by at least 1cm of skin\n\n        Exclusion Criteria:\n\n          -  For women, a positive pregnancy test and/or nursing at screening\n\n          -  A positive test for drugs of abuse at screening\n\n          -  History of alcohol or illicit drug abuse\n\n          -  Positive test results for Hepatitis B, Hepatitis C or HIV\n\n          -  Have used salicylic acid or any other over-the-counter- wart-removing product in the\n             treatment area within 30 days prior to enrollment\n\n          -  Have received cryotherapy in the treatment area within 60 days prior to enrollment\n\n          -  Have required systemic intake of immunosuppressive or immunomodulatory medication\n             (including oral or parenteral corticosteroids) with 30 days prior to enrollment or\n             during the course of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106260", 
            "org_study_id": "CLS003-CO-PR-001"
        }, 
        "intervention": {
            "arm_group_label": "CLS003", 
            "intervention_name": "CLS003", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "safety", 
            "pharmacokinetics (PK)", 
            "pharmacodynamics (PD)", 
            "CLS003"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zernikedreef 8", 
                    "country": "Netherlands"
                }, 
                "name": "Centre for Human Drug Research"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/IIa Open-label First-in-Human Study to Assess Safety and Pharmacokinetics and Explore Biomarker Effects of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Subjects With Cutaneous Warts", 
        "overall_official": {
            "affiliation": "Centre for Human Drug Research", 
            "last_name": "J. (Koos) Burggraaf, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of CLS003", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of CLS003", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Time to reach Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacodynamic effects of topically applied CLS003 on wart morphology and HPV viral load", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "source": "Cutanea Life Sciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cutanea Life Sciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}